Jacobi Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Jacobi Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,500	Closed	-$32K	–	596
2021 Q3	$32K	Hold	1,500	–	–	﹤0.01%	754
2021 Q2	$28K	Hold	1,500	–	–	﹤0.01%	756
2021 Q1	$23K	Hold	1,500	–	–	﹤0.01%	743
2020 Q4	$21K	Sell	1,500 -1,500	-50%	-$20.9K	﹤0.01%	705
2020 Q3	$47K	Hold	3,000	–	–	0.01%	512
2020 Q2	$53K	Hold	3,000	–	–	0.01%	459
2020 Q1	$44K	Hold	3,000	–	–	0.01%	438
2019 Q4	$75K	Hold	3,000	–	–	0.01%	394
2019 Q3	$45K	Hold	3,000	–	–	0.01%	478
2019 Q2	$75K	Buy	+3,000	New	+$74.3K	0.02%	380

Other funds holding CRNX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Jacobi Capital Management's CRNX Position: Q4 2021 in Review

Jacobi Capital Management sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2021, closing a stake of 1,500 shares — an estimated $32K sold.

Jacobi Capital Management first reported a position in CRNX in Q2 2019 and held it in 10 quarters. The position peaked at $75K in Q4 2019. 118 funds tracked by Wall St. Rank hold CRNX as of Q4 2021.

Jacobi Capital Management reported no remaining Crinetics Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Jacobi Capital Management sold 1,500 Crinetics Pharmaceuticals shares in Q4 2021, an estimated $32K.
Jacobi Capital Management first reported a position in Crinetics Pharmaceuticals in Q2 2019 and held it in 10 quarters.
Jacobi Capital Management's Crinetics Pharmaceuticals position peaked at $75K in Q4 2019.
118 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2021.

Based on Jacobi Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.